Expanding global access to mRNA vaccines
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).10.1038/s41573-021-00283-5 ↗
2. Leong, K. Y., Tham, S. K. & Poh, C. L. Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications. Virol. J. 22, 71 (2025).10.1186/s12985-025-02645-6 ↗
3. Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 7, 94 (2022).10.1038/s41392-022-00950-y ↗
4. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).10.1056/NEJMoa2035389 ↗
5. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).10.1056/NEJMoa2034577 ↗
6. Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).10.1038/nrd.2017.243 ↗
7. Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).10.1038/nrd4278 ↗
8. Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).10.1038/s41392-022-01007-w ↗
9. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).10.1038/s41587-022-01294-2 ↗
10. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
11. Li, S., Zheng, L., Zhong, J. & Gao, X. Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progress. Essays Biochem. https://doi.org/10.1042/ebc20253009 (2025).10.1042/ebc20253009 ↗
12. Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases — advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838–861 (2024).10.1038/s41573-024-01042-y ↗
13. Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526–543 (2023).10.1038/s41568-023-00586-2 ↗
14. Sayour, E. J., Boczkowski, D., Mitchell, D. A. & Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 21, 489–500 (2024).10.1038/s41571-024-00902-1 ↗
15. Deyhimfar, R. et al. The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases. Heliyon 10, e26971 (2024).10.1016/j.heliyon.2024.e26971 ↗
16. Youssef, M., Hitti, C., Puppin Chaves Fulber, J. & Kamen, A. A. Enabling mRNA therapeutics: current landscape and challenges in manufacturing. Biomolecules 13, 1497 (2023).10.3390/biom13101497 ↗
17. Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. & Marques, M. P. C. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39, 2190–2200 (2021).10.1016/j.vaccine.2021.03.038 ↗
18. Wells, C. R. & Galvani, A. P. The global impact of disproportionate vaccination coverage on COVID-19 mortality. Lancet Infect. Dis. 22, 1254–1255 (2022).10.1016/S1473-3099(22)00417-0 ↗
19. Street, A., Kersaudy Kerhoas, M. & Ndlovu, Z. From equitable access to equitable innovation: rethinking bioengineering for global health. Nat. Rev. Bioeng. 2, 444–446 (2024).10.1038/s44222-024-00182-5 ↗
20. Dzau, V. et al. The 100 days mission: how a new medical-countermeasures network can deliver equity and innovation. Lancet 402, 1507–1510 (2023).10.1016/S0140-6736(23)01775-0 ↗
21. Zhang, G., Tang, T., Chen, Y., Huang, X. & Liang, T. mRNA vaccines in disease prevention and treatment. Signal Transduct. Target. Ther. 8, 365 (2023).10.1038/s41392-023-01579-1 ↗
22. May, M. After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases. Nat. Med. 27, 930–932 (2021).10.1038/s41591-021-01393-8 ↗
23. Paczkowska, A. et al. The application of mRNA technology for vaccine production—current state of knowledge. Vaccines 13, 389 (2025).10.3390/vaccines13040389 ↗
24. Kaylor, A. Moderna’s COVID-19 vaccine mNEXSPIKE gains FDA approval. TechTarget https://www.techtarget.com/pharmalifesciences/news/366625275/Modernas-COVID-19-vaccine-mNEXSPIKE-gains-FDA-approval (2 June 2025).
25. Saraf, A. et al. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial. Nat. Med. 30, 1363–1372 (2024).10.1038/s41591-024-02955-2 ↗
26. Dolgin, E. Self-copying RNA vaccine wins approval: what’s next? Nature 624, 14 (2023).10.1038/d41586-023-03859-w ↗
27. Silva-Pilipich, N., Beloki, U., Salaberry, L. & Smerdou, C. Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. Vaccines 12, 318 (2024).10.3390/vaccines12030318 ↗
28. Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233–2244 (2023).10.1056/NEJMoa2307079 ↗
29. Chuang, Y.-M. et al. A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria. npj Vaccines 8, 88 (2023).10.1038/s41541-023-00679-x ↗
30. Matarazzo, L. & Bettencourt, P. J. G. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. Front. Immunol. 14, 1172691 (2023).10.3389/fimmu.2023.1172691 ↗
31. Vidal, S. J. et al. Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines. Cell https://doi.org/10.1016/j.cell.2025.08.027 (2025). This article reports a systematic CD4+ T cell antigen screen that identifies a trivalent mRNA–LNP tuberculosis vaccine candidate with translational potential.10.1016/j.cell.2025.08.027 ↗
32. Rudman Spergel, A. K. et al. mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial. Nat. Med. 31, 1484–1493 (2025).10.1038/s41591-025-03591-0 ↗
33. Zubair, A., Ahmad, H., Arif, M. M. & Ali, M. mRNA vaccines against HIV: hopes and challenges. HIV Med. 26, 824–838 (2025).10.1111/hiv.70024 ↗
34. Lusso, P. in Trends in mRNA Vaccine Research (eds Szabo, G. T. & Pardi, N.) 259–283 (Wiley, 2025).10.1002/9783527838394.ch9 ↗
35. Cevaal, P. M. et al. Efficient mRNA delivery to resting T cells to reverse HIV latency. Nat. Commun. 16, 4979 (2025).10.1038/s41467-025-60001-2 ↗
36. Morris, L. mRNA vaccines offer hope for HIV. Nat. Med. 27, 2082–2084 (2021).10.1038/s41591-021-01602-4 ↗
37. Willis, J. R. et al. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science 389, eadr8382 (2025).10.1126/science.adr8382 ↗
38. Parks, K. R. et al. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci. Transl. Med. 17, eady6831 (2025).10.1126/scitranslmed.ady6831 ↗
39. Shim, I., Rogowski, L. & Venketaraman, V. Progress and recent developments in HIV vaccine research. Vaccines 13, 690 (2025).10.3390/vaccines13070690 ↗
40. Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct. Target. Ther. 8, 450 (2023).10.1038/s41392-023-01674-3 ↗
41. Lorentzen, C. L., Haanen, J. B., Met, Ö. & Svane, I. M. Clinical advances and ongoing trials of mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450–e458 (2022).10.1016/S1470-2045(22)00372-2 ↗
42. Goyal, F. et al. Advancing cancer immunotherapy: the potential of mRNA vaccines as a promising therapeutic approach. Adv. Ther. 7, 2300255 (2024).10.1002/adtp.202300255 ↗
43. Türeci, Ö. et al. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin. Cancer Res. 22, 1885–1896 (2016).10.1158/1078-0432.CCR-15-1509 ↗
44. Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024). This article reports results from a randomized phase IIb trial showing that an individualized neoantigen mRNA vaccine (mRNA-4157/V940) combined with pembrolizumab improves recurrence-free survival compared with pembrolizumab alone in patients with resected high-risk melanoma.10.1016/S0140-6736(23)02268-7 ↗
45. Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).10.1038/s41586-023-06063-y ↗
46. Damle, S. R., Pillarisetty, V. G., Safyan, R. A. & Chiorean, E. G. A new dawn in cancer immunotherapy: the promise of mutant KRAS-specific vaccines. Transl. Gastroenterol. Hepatol. 10, 20 (2025).10.21037/tgh-24-121 ↗
47. Fu, Q. et al. mRNA vaccines in the context of cancer treatment: from concept to application. J. Transl. Med. 23, 12 (2025).10.1186/s12967-024-06033-6 ↗
48. Fu, R. et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct. Target. Ther. 9, 118 (2024).10.1038/s41392-024-01824-1 ↗
49. Shariati, A. et al. mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy. Biomark. Res. 12, 157 (2024).10.1186/s40364-024-00692-9 ↗
50. Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022).10.1038/s41587-022-01491-z ↗
51. Koeberl, D. et al. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. Nature 628, 872–877 (2024).10.1038/s41586-024-07266-7 ↗
52. Attarwala, H., Lumley, M., Liang, M., Ivaturi, V. & Senn, J. Translational pharmacokinetic/pharmacodynamic model for mRNA-3927, an investigational therapeutic for the treatment of propionic acidemia. Nucleic Acid Ther. 33, 141–147 (2023).10.1089/nat.2022.0036 ↗
53. Baek, R. et al. Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria. Nat. Commun. 15, 3804 (2024).10.1038/s41467-024-47460-9 ↗
54. Geller, D. E., Crowley, C., Froehlich, J., Schwabe, C. & O’Carroll, M. WS10.03 Inhaled LUNAR®-CFTR mRNA (ARCT-032) is safe and well-tolerated: a phase 1 study. J. Cyst. Fibros. 23, S19 (2024).10.1016/S1569-1993(24)00166-8 ↗
55. Rowe, S. M. et al. Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J. Cyst. Fibros. 22, 656–664 (2023).10.1016/j.jcf.2023.04.008 ↗
56. Żak, M. M. & Zangi, L. Clinical development of therapeutic mRNA applications. Mol. Ther. 33, 2583–2609 (2025).10.1016/j.ymthe.2025.03.034 ↗
57. Zouali, M. Inverse vaccination for autoimmune diseases: insights into the role of B lymphocytes. Cells 14, 1085 (2025).10.3390/cells14141085 ↗
58. Zala, A. & Thomas, R. Antigen-specific immunotherapy to restore antigen-specific tolerance in type 1 diabetes and Graves’ disease. Clin. Exp. Immunol. 211, 164–175 (2023).10.1093/cei/uxac115 ↗
59. Chen, J. et al. LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice. J. Control. Release 375, 513–523 (2024).10.1016/j.jconrel.2024.09.020 ↗
60. Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145–153 (2021).10.1126/science.aay3638 ↗
61. Liu, Y. et al. Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-025-01373-0 (2025). This article reports the in vivo generation of tolerogenic antigen-presenting cells through LNP delivery of mRNA encoding PD-L1, suppressing T cell activation and preventing disease progression in mouse models of autoimmune disease.10.1038/s41551-025-01373-0 ↗
62. Liric Rajlic, I. et al. Translational kinetic-pharmacodynamics of mRNA-6231, an investigational mRNA therapeutic encoding mutein interleukin-2. CPT Pharmacomet. Syst. Pharmacol. 13, 1067–1078 (2024).10.1002/psp4.13142 ↗
63. Shi, Y., Shi, M., Wang, Y. & You, J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct. Target. Ther. 9, 322 (2024).10.1038/s41392-024-02002-z ↗
64. Hewitt, S. L. et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci. Transl. Med. 11, eaat9143 (2019).10.1126/scitranslmed.aat9143 ↗
65. Hamouda, A. E. I. et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat. Commun. 15, 10635 (2024).10.1038/s41467-024-54877-9 ↗
66. Li, Z. et al. Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity. Front. Immunol. 15, 1455019 (2024).10.3389/fimmu.2024.1455019 ↗
67. Gote, V. et al. A comprehensive review of mRNA vaccines. Int. J. Mol. Sci. 24, 2700 (2023).10.3390/ijms24032700 ↗
68. Yeh, T.-F., Lin, C. & Sung, H.-C. A review of technological developments in lipid nanoparticle application for mRNA vaccination. Hum. Vaccines Immunother. 19, 2256040 (2023).10.1080/21645515.2023.2256040 ↗
69. Lu, Y. et al. Advancing mRNA vaccines: a comprehensive review of design, delivery, and efficacy in infectious diseases. Int. J. Biol. Macromol. 319, 145501 (2025).10.1016/j.ijbiomac.2025.145501 ↗
70. Kim, Y.-A. et al. Computational design of mRNA vaccines. Vaccine 42, 1831–1840 (2024).10.1016/j.vaccine.2023.07.024 ↗
71. Dolgin, E. ‘Remarkable’ AI tool designs mRNA vaccines that are more potent and stable. Nature https://doi.org/10.1038/d41586-023-01487-y (2023).10.1038/d41586-023-01487-y ↗
72. Castillo-Hair, S. M. & Seelig, G. Machine learning for designing next-generation mRNA therapeutics. Acc. Chem. Res. 55, 24–34 (2022).10.1021/acs.accounts.1c00621 ↗
73. Castillo-Hair, S. et al. Optimizing 5′UTRs for mRNA-delivered gene editing using deep learning. Nat. Commun. 15, 5284 (2024).10.1038/s41467-024-49508-2 ↗
74. Kosuri, S. & Church, G. M. Large-scale de novo DNA synthesis: technologies and applications. Nat. Methods 11, 499–507 (2014).10.1038/nmeth.2918 ↗
75. Bang, D. & Church, G. M. Gene synthesis by circular assembly amplification. Nat. Methods 5, 37–39 (2008).10.1038/nmeth1136 ↗
76. Karikó, K., Muramatsu, H., Ludwig, J. & Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011).10.1093/nar/gkr695 ↗
77. Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines 5, 11 (2020).10.1038/s41541-020-0159-8 ↗
78. Verbeke, R., Lentacker, I., De Smedt, S. C. & Dewitte, H. The dawn of mRNA vaccines: the COVID-19 case. J. Control. Release 333, 511–520 (2021).10.1016/j.jconrel.2021.03.043 ↗
79. Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).10.1016/j.ijpharm.2021.120586 ↗
80. Verbeke, R., Lentacker, I., De Smedt, S. C. & Dewitte, H. Three decades of messenger RNA vaccine development. Nano Today 28, 100766 (2019).10.1016/j.nantod.2019.100766 ↗
81. Roces, C. B. et al. Manufacturing considerations for the development of lipid nanoparticles using microfluidics. Pharmaceutics 12, 1095 (2020).10.3390/pharmaceutics12111095 ↗
82. Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017).10.1016/j.ymthe.2017.03.013 ↗
83. Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. & Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. J. Pharm. Sci. 110, 997–1001 (2021).10.1016/j.xphs.2020.12.006 ↗
84. Wouters, O. J. et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 397, 1023–1034 (2021).10.1016/S0140-6736(21)00306-8 ↗
85. Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R. & Shah, N. Rapid development and deployment of high-volume vaccines for pandemic response. J. Adv. Manuf. Process. 2, e10060 (2020).10.1002/amp2.10060 ↗
86. vander Straeten, A. et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat. Biotechnol. 42, 510–517 (2024). This article reports a standalone microneedle vaccine printer that enables decentralized manufacture of thermostable mRNA–LNP COVID-19 vaccines without cold-chain requirements.10.1038/s41587-023-01774-z ↗
87. Han, J. et al. On-patient medical record and mRNA therapeutics using intradermal microneedles. Nat. Mater. 24, 794–803 (2025). This article reports a quantum dot-encoded on-patient medical record platform using microneedles delivering mRNA–LNP vaccine, enabling reliable tracking of vaccine administration in low-resource settings.10.1038/s41563-024-02115-4 ↗
88. Skerritt, J. H., Tucek-Szabo, C., Sutton, B. & Nolan, T. The platform technology approach to mRNA product development and regulation. Vaccines 12, 528 (2024).10.3390/vaccines12050528 ↗
89. Knezevic, I., Liu, M. A., Peden, K., Zhou, T. & Kang, H.-N. Development of mRNA vaccines: scientific and regulatory issues. Vaccines 9, 81 (2021).10.3390/vaccines9020081 ↗
90. Skerritt, J. H. Considerations for mRNA product development, regulation and deployment across the lifecycle. Vaccines 13, 473 (2025).10.3390/vaccines13050473 ↗
91. Daniel, S., Kis, Z., Kontoravdi, C. & Shah, N. Quality by design for enabling RNA platform production processes. Trends Biotechnol. 40, 1213–1228 (2022).10.1016/j.tibtech.2022.03.012 ↗
92. Gunter, H. M. et al. mRNA vaccine quality analysis using RNA sequencing. Nat. Commun. 14, 5663 (2023).10.1038/s41467-023-41354-y ↗
93. Jones, C. H. et al. Breaking the mold with RNA—a “RNAissance” of life science. npj Genom. Med. 9, 2 (2024).10.1038/s41525-023-00387-4 ↗
94. Patel, P. et al. Regulatory agilities impacting review timelines for Pfizer/BioNTech’s BNT162b2 mRNA COVID-19 vaccine: a retrospective study. Front. Med. 10, 1275817 (2023).10.3389/fmed.2023.1275817 ↗
95. Bouderhem, R. Challenges faced by states and the WHO in efficiently regulating the use of mRNA vaccines. Med. Sci. Forum 26, 1 (2024).
96. Cavaleri, M. et al. A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems. Lancet Glob. Health 13, e769–e777 (2025).10.1016/S2214-109X(24)00515-1 ↗
97. Chisholm, O. & Critchley, H. Future directions in regulatory affairs. Front. Med. 9, 1082384 (2022).10.3389/fmed.2022.1082384 ↗
98. Slaoui, M. & Hepburn, M. Developing safe and effective covid vaccines — operation warp speed’s strategy and approach. N. Engl. J. Med. 383, 1701–1703 (2020).10.1056/NEJMp2027405 ↗
99. Rathore, A. S. & Winkle, H. Quality by design for biopharmaceuticals. Nat. Biotechnol. 27, 26–34 (2009).10.1038/nbt0109-26 ↗
100. Bouderhem, R. Access to COVID-19 vaccines: a new global approach. Vaccines 10, 1795 (2022).10.3390/vaccines10111795 ↗